167 related articles for article (PubMed ID: 29299946)
1. A new approach for modeling patient overall radiosensitivity and predicting multiple toxicity endpoints for breast cancer patients.
Mbah C; De Ruyck K; De Schrijver S; De Sutter C; Schiettecatte K; Monten C; Paelinck L; De Neve W; Thierens H; West C; Amorim G; Thas O; Veldeman L
Acta Oncol; 2018 May; 57(5):604-612. PubMed ID: 29299946
[TBL] [Abstract][Full Text] [Related]
2. In vitro cellular radiosensitivity in relationship to late normal tissue reactions in breast cancer patients: a multi-endpoint case-control study.
Vandevoorde C; Depuydt J; Veldeman L; De Neve W; Sebastià N; Wieme G; Baert A; De Langhe S; Philippé J; Thierens H; Vral A
Int J Radiat Biol; 2016 Dec; 92(12):823-836. PubMed ID: 27586010
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis.
Korzets Y; Fyles A; Shepshelovich D; Amir E; Goldvaser H
Breast Cancer Res Treat; 2019 Jun; 175(3):531-545. PubMed ID: 30929116
[TBL] [Abstract][Full Text] [Related]
4. Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer.
Barber JB; Burrill W; Spreadborough AR; Levine E; Warren C; Kiltie AE; Roberts SA; Scott D
Radiother Oncol; 2000 May; 55(2):179-86. PubMed ID: 10799730
[TBL] [Abstract][Full Text] [Related]
5. Clinical correlations between late normal tissue endpoints after radiotherapy: implications for predictive assays of radiosensitivity.
Bentzen SM; Overgaard M; Overgaard J
Eur J Cancer; 1993; 29A(10):1373-6. PubMed ID: 8398261
[TBL] [Abstract][Full Text] [Related]
6. Clinical and cosmetic results of breast boost radiotherapy in early breast cancer: a randomized study between electron and photon.
Rajan SS; Sharma SC; Kumar N; Kumar R; Singh G; Singh R; Tomar P
J Cancer Res Ther; 2014; 10(4):889-95. PubMed ID: 25579524
[TBL] [Abstract][Full Text] [Related]
7. A phase II study investigating the acute toxicity of targeted intraoperative radiotherapy as tumor-bed boost plus whole breast irradiation after breast-conserving surgery in Korean patients.
Ahn SG; Bae SJ; Lee HW; Yoon CI; Kim JW; Lee IJ; Jeong J
Breast Cancer Res Treat; 2019 Feb; 174(1):157-163. PubMed ID: 30467660
[TBL] [Abstract][Full Text] [Related]
8. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.
Polgár C; Ott OJ; Hildebrandt G; Kauer-Dorner D; Knauerhase H; Major T; Lyczek J; Guinot JL; Dunst J; Miguelez CG; Slampa P; Allgäuer M; Lössl K; Polat B; Kovács G; Fischedick AR; Fietkau R; Resch A; Kulik A; Arribas L; Niehoff P; Guedea F; Schlamann A; Pötter R; Gall C; Uter W; Strnad V;
Lancet Oncol; 2017 Feb; 18(2):259-268. PubMed ID: 28094198
[TBL] [Abstract][Full Text] [Related]
9. Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy.
Johansen J; Bentzen SM; Overgaard J; Overgaard M
Radiother Oncol; 1996 Aug; 40(2):101-9. PubMed ID: 8884963
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
Sjöström M; Staaf J; Edén P; Wärnberg F; Bergh J; Malmström P; Fernö M; Niméus E; Fredriksson I
Breast Cancer Res; 2018 Jul; 20(1):64. PubMed ID: 29973242
[TBL] [Abstract][Full Text] [Related]
11. Accelerated partial breast irradiation-Redefining the treatment target for women with early stage breast cancer.
Shah C; Vicini F
Breast J; 2019 May; 25(3):408-417. PubMed ID: 30950133
[TBL] [Abstract][Full Text] [Related]
12. Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity.
Reuther S; Szymczak S; Raabe A; Borgmann K; Ziegler A; Petersen C; Dikomey E; Hoeller U
Strahlenther Onkol; 2015 Jan; 191(1):59-66. PubMed ID: 25156511
[TBL] [Abstract][Full Text] [Related]
13. Incidental dose to coronary arteries is higher in prone than in supine whole breast irradiation. A dosimetric comparison in adjuvant radiotherapy of early stage breast cancer.
Würschmidt F; Stoltenberg S; Kretschmer M; Petersen C
Strahlenther Onkol; 2014 Jun; 190(6):563-8. PubMed ID: 24604557
[TBL] [Abstract][Full Text] [Related]
14. Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
Andreassen CN; Rosenstein BS; Kerns SL; Ostrer H; De Ruysscher D; Cesaretti JA; Barnett GC; Dunning AM; Dorling L; West CML; Burnet NG; Elliott R; Coles C; Hall E; Fachal L; Vega A; Gómez-Caamaño A; Talbot CJ; Symonds RP; De Ruyck K; Thierens H; Ost P; Chang-Claude J; Seibold P; Popanda O; Overgaard M; Dearnaley D; Sydes MR; Azria D; Koch CA; Parliament M; Blackshaw M; Sia M; Fuentes-Raspall MJ; Ramon Y Cajal T; Barnadas A; Vesprini D; Gutiérrez-Enríquez S; Mollà M; Díez O; Yarnold JR; Overgaard J; Bentzen SM; Alsner J;
Radiother Oncol; 2016 Dec; 121(3):431-439. PubMed ID: 27443449
[TBL] [Abstract][Full Text] [Related]
15. Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.
Cui Y; Li B; Pollom EL; Horst KC; Li R
Clin Cancer Res; 2018 Oct; 24(19):4754-4762. PubMed ID: 29921729
[No Abstract] [Full Text] [Related]
16. Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity.
Dorling L; Barnett GC; Michailidou K; Coles CE; Burnet NG; Yarnold J; Elliott RM; Dunning AM; Pharoah PD; West CM
Clin Cancer Res; 2016 Mar; 22(6):1413-20. PubMed ID: 26510858
[TBL] [Abstract][Full Text] [Related]
17. Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer.
Russell NS; Grummels A; Hart AA; Smolders IJ; Borger J; Bartelink H; Begg AC
Int J Radiat Biol; 1998 Jun; 73(6):661-70. PubMed ID: 9690684
[TBL] [Abstract][Full Text] [Related]
18. Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer.
Arsenault J; Parpia S; Goldberg M; Rakovitch E; Reiter H; Doherty M; Lukka H; Sussman J; Wright J; Julian J; Whelan T
Int J Radiat Oncol Biol Phys; 2020 Aug; 107(5):943-948. PubMed ID: 32334033
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer.
Brock WA; Tucker SL; Geara FB; Turesson I; Wike J; Nyman J; Peters LJ
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1371-9. PubMed ID: 7635777
[TBL] [Abstract][Full Text] [Related]
20. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
